Predisposition to common human diseases is frequently associated with polymorphisms in distal control regions, also known as gene enhancers. Li et al. (Li et al., 2013 ) evaluated the relative contributions of somatic and germline mutations to intertumor gene expression variation, with the aim of revealing links between genomic regions associated with cancer susceptibility and the expression of genes involved in cancer development. The authors assessed the contribution of DNA methylation in gene promoters to variation in intertumor gene expression and found that 3.3% of this variation can be attributed to methylation variation. However, methylation could provide a higher level of contribution to tumor heterogeneity and may further illuminate the mechanism of cancer predisposition, if the methylation of enhancer sites was also taken into account. Enhancer methylation is drastically altered in cancers and is closely related to altered expression profiles of cancer genes (Aran et al., 2013) . Therefore, we have extended the analysis of Li et al. to include methylation sites in distal enhancers. The results indicate that enhancer methylation status data can contribute to the elucidation of the regulatory circuits linking cancer risk loci with expression profiles of cancerrelated genes.
We analyzed 390 estrogen receptor (ER)-positive breast tumors for which genomic methylation and expression data were available at The Cancer Genome Atlas (TCGA) website. To focus on distal enhancers, we omitted from the analysis methylation sites at <5 kb from transcription start sites (TSSs). Using published data on physical coupling between distal regions and gene promoters in MCF-7 cells (Li et al., 2012) , we evaluated the correlation of enhancer methylation sites with the expression of the target genes. Out of 10,361 CpG site-gene pairs, 942 CpGs were significantly correlated (R 2 > 0.1, p < 0.05) with the expression of 786 genes. In 73.2% of the genes, distal methylation sites characterized expression levels better than promoter methylation ( Figure 1A ). Moreover, expression variation of 49.2% of the genes was exclusively explained by enhancer methylations, whereas promoter methylation showed no correlation with expression. Overall, enhancer methylation explained 4.0% of intertumor gene expression variation in addition to the fraction explained by promoter methylation. We thus explored whether enhancer methylation links cancer susceptibility loci with cancer-driving mechanisms. Indeed, we found that known breast-cancer-associated risk loci (genome-wide association study [GWAS] catalog) are significantly enriched (p < 0.00002) with enhancer methylation sites correlated with intertumor expression variation ( Figure 1B) . Markedly, expression levels of Cyclin D1 (CCND1), a prominent breast cancer oncogene and a known target of the estrogen receptor gene ESR1, showed close relationships with the methylation of five enhancer sites within a breast-cancer-associated region ( Figure 1C) . Furthermore, other key drivers of breast cancer, including ESR1 itself and MAP3K1, were also correlated with methylation sites located in enhancer regions within breast cancer risk loci ( Figure 1D ). We also assessed the relationships between DNA methylation and estrogen receptor alpha (ER-a, the product of the ESR1 gene, a key regulator of breast cancer genes) binding levels in MCF-7 cells, utilizing an independent database (Fullwood et al., 2009 ). The results showed that ER-a binds enhancer sites in a methylation-related manner ( Figure 1E ), thus revealing a mechanistic link between breast cancer enhancer activity and DNA methylation levels. Hence, the analysis of enhancer methylation revealed regulatory connections between breast cancer risk loci and genes driving breast cancer development.
Although transgenerational transmission of methylation polymorphisms is infrequent in the human genome, methylation analysis may be crucial for the understanding of germline-transmitted cancer predisposition. As shown by Li et al., the assessment of direct associations between polymorphic sequences and gene expression only revealed mechanistic links in a subset of the analyzed loci (6 out of 15). Elucidating the biology of the remaining sites may require understanding of genetic-epigenetic interactions (Kim et al., 2013) . Based on our findings we suggest that enhancer sites contain both sequence and methylation polymorphisms that define enhancer activity. However, the correlation of polymorphic sequences with gene expression is apparently low, whereas the correlation between expression and methylation is considerably higher ( Figure 1F) . A recent extensive analysis provides further experimental support for the above model: applying chromatin conformation capturing and luciferase reporter assays, a region upstream to the CCND1 gene was shown to contain functional enhancers of the gene (French et al., 2013) . Sequence variants within these enhancers were associated with breast cancer risk, but, as in the Li et al. study, showed no significant correlation with CCND1 expression level, thus failing to link risk sequence alleles with breast cancer mechanism. In contrast, our analysis revealed a striking correlation of CCND1 expression level with methylation of the very same enhancer region sites ( Figure 1C) , thus providing the missing link between this cancer risk locus and mechanism. Additional risk loci in various cancers and other common diseases may also be explored using this approach.
We have shown that enhancer methylation accounts for a significant portion of intertumor expression heterogeneity. Many enhancer sites predict gene expression levels better than promoter methylation. Remarkably, cancer risk loci are significantly enriched by expression-related methylation sites. The analysis of these sites revealed novel regulatory connections with drivers of breast cancer development. We suggest that exploration of distal DNA methylation sites and their interactions with germline polymorphisms can enhance understanding of the biology behind cancer predisposition.
